ACOR Acorda Therapeutics, Inc.

15.95
0  0%
Previous Close 16.00
Open 16.00
Price To book 1.10
Market Cap 728.39M
Shares 45,667,000
Volume 638,105
Short Ratio 5.25
Av. Daily Volume 1,186,140

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 2 to be initiated by the end of 2017.
CVT-427
Migraine
Phase 3 data due 1Q 2018.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing due by the end of 2Q 2017.
CVT-301
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. Acorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017
  2. Bass Battled U.S. Drug Patents and Prices But Lost to ‘Cabal’
  3. ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm
  4. Acorda Trims 20% Of Workforce, But Looming Cuts Could Be Deeper
  5. Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
  6. Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired
  7. Acorda Therapeutics to cut 20 pct of workforce
  8. Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs
  9. Why Acorda Therapeutics Inc Plummeted for a Second Straight Day
  10. Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight
  11. Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge
  12. Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : April 3, 2017
  13. Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic
  14. Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today
  15. Acorda, Forward Stocks Plunge On Multiple Sclerosis Court Rulings
  16. Acorda Loses Multiple Sclerosis Drug Patents
  17. Two biotech stocks plunge after losing patent fights
  18. Acorda Therapeutics' stock plummets toward biggest-ever loss amid disappointing patent ruling
  19. Acorda Therapy tanks
  20. U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling